Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab and Venetoclax Maintenance for Ph-Negative B-ALL Post-Transplant
NCT07199855Phase 2Active, not recruiting
- Sponsor
- Zhejiang University
- Start
- Jun 2025
- Primary completion
- Jun 2027
- Modality
- Antibody Conjugates, scFv Fragments, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab and venetoclax in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Zhejiang University. Primary endpoint: Progression-Free Survival at 2 years. Started Jun 2025; status: active, not recruiting.
02
Drugs
blinatumomabvenetoclax
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07199855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07199855.